Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1993 1
1994 1
1995 2
1996 2
1997 3
1999 2
2001 2
2002 3
2003 2
2004 2
2007 2
2008 5
2009 2
2010 2
2011 2
2012 4
2013 4
2014 1
2015 4
2016 4
2017 7
2018 2
2019 4
2020 3
2021 6
2022 4
2023 7
2024 8
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Fizazi K, et al. N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4. N Engl J Med. 2017. PMID: 28578607 Free article. Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Liquid Biopsy in Glioblastoma.
Ronvaux L, Riva M, Coosemans A, Herzog M, Rommelaere G, Donis N, D'Hondt L, Douxfils J. Ronvaux L, et al. Among authors: d hondt l. Cancers (Basel). 2022 Jul 13;14(14):3394. doi: 10.3390/cancers14143394. Cancers (Basel). 2022. PMID: 35884454 Free PMC article. Review.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Ann Oncol. 2025 Feb;36(2):185-196. doi: 10.1016/j.annonc.2024.10.828. Epub 2024 Nov 9. Ann Oncol. 2025. PMID: 39528049 Free article. Clinical Trial.
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
Brain E, Mir O, Bourbouloux E, Rigal O, Ferrero JM, Kirscher S, Allouache D, D'Hondt V, Savoye AM, Durando X, Duhoux FP, Venat-Bouvet L, Blot E, Canon JL, Rollot-Trad F, Bonnefoi H, Roque T, Lemonnier J, Latouche A, Henriques J, Lacroix-Triki M, Vernerey D; GERICO&UCBG/Unicancer. Brain E, et al. Lancet. 2025 Aug 2;406(10502):489-500. doi: 10.1016/S0140-6736(25)00832-3. Lancet. 2025. PMID: 40752909 Clinical Trial.
Neutrophilic eccrine hidradenitis.
D'Hondt L, Doyen C, Chatelain C, Dumont M, Bosly A. D'Hondt L, et al. Acta Clin Belg. 1994;49(2):114. doi: 10.1080/17843286.1994.11718375. Acta Clin Belg. 1994. PMID: 8067173 No abstract available.
Refractory thyroid carcinoma: which systemic treatment to use?
Faugeras L, Pirson AS, Donckier J, Michel L, Lemaire J, Vandervorst S, D'Hondt L. Faugeras L, et al. Among authors: d hondt l. Ther Adv Med Oncol. 2018 Jan 23;10:1758834017752853. doi: 10.1177/1758834017752853. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29399055 Free PMC article. Review.
Stem cell engraftment strategies.
Quesenberry PJ, Stewart FM, Becker P, D'Hondt L, Frimberger A, Lambert JF, Colvin GA, Miller C, Heyes C, Abedi M, Dooner M, Carlson J, Reilly J, McAuliffe C, Stencel K, Ballen K, Emmons R, Doyle P, Zhong S, Wang H, Habibian H. Quesenberry PJ, et al. Among authors: d hondt l. Ann N Y Acad Sci. 2001 Jun;938:54-61; discussion 61-2. doi: 10.1111/j.1749-6632.2001.tb03574.x. Ann N Y Acad Sci. 2001. PMID: 11458526 Review.
Assisting walking balance using a bio-inspired exoskeleton controller.
Afschrift M, van Asseldonk E, van Mierlo M, Bayon C, Keemink A, D'Hondt L, van der Kooij H, De Groote F. Afschrift M, et al. Among authors: d hondt l. J Neuroeng Rehabil. 2023 Jun 27;20(1):82. doi: 10.1186/s12984-023-01205-9. J Neuroeng Rehabil. 2023. PMID: 37370175 Free PMC article.
93 results